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Introduction
The major inhibitory receptor in the mammalian central nervous system is the γ-aminobutyric acid type A (GABAA) receptor. This receptor is composed of five homologous subunits, arranged around a central Cl -selective channel (Macdonald et al. 1994) . While 19 subunits have been cloned (Macdonald et al. 1994; Barnard et al. 1998; Olsen et al. 2008; Sigel and Steinmann 2012) , the majority of GABAA receptors in the brain consist of α1, β2 and γ2
subunits (Macdonald et al. 1994; Rabow et al. 1995; Barnard et al. 1998; Olsen et al. 2008; Sigel and Steinmann 2012) . Subunit composition and arrangement both affect the pharmacological properties of GABAA receptors (Sigel et al. 1990; Sieghart 1995; Minier and Sigel 2004 ). In the following we assume that the α1β2γ2 GABAA receptor has the subunit arrangement γ2β2α1β2α1 and the α1β2 receptor has the subunit arrangement β2β2α1β2α1 (Baumann et al. 2001) .
Several clinically and experimentally used drugs exert their action via GABAA receptors, including benzodiazepines, barbiturates, and the intravenous anesthetics propofol and etomidate (Sieghart 1995; Rudolph et al. 1999; Nishikawa et al. 2002; Jurd et al. 2003; Sieghart and Ernst 2005; Li et al. 2006; Yip et al. 2013; Middendorp et al. 2014) . A high affinity benzodiazepine binding site on α1β2γ2 GABAA receptors is located at the α+/γ− subunit interface in the extracellular domain (Sigel 2002; Sigel and Lüscher 2011) . This site is homologous to the GABA binding sites at β+/α− interfaces Sigel and Lüscher 2011) . In addition to the high affinity binding site for benzodiazepines (site 1), there are other low affinity sites. One of these, site 2, is thought to be located at the α+/β− interface in the extracellular domain (Baur et al. 2008) . Later it has been postulated that the pyrazoloquinoline CGS 9895 acts in a similar location (Ramerstorfer et al. 2011) .
Interestingly, an ethanol antagonist site at the same subunit interface has been postulated in extrasynaptic δ subunit containing receptors (Wallner et al. 2014) . Other sites designated as sites 3 (Middendorp et al. 2015) , are located in the membrane and have been shown to be abolished by combined mutations to isoleucine of the homologous residues α1S269, β2N265, and γ2S280 (Walters et al. 2000) .
It has been demonstrated that CGS 9895 at nM concentrations is a null modulator at site 1, and at µM concentrations a positive allosteric modulator acting at the α+/β− interface in the extracellular domain (Ramerstorfer et al. 2011) . The localization of the binding site for CGS 9895 was based on a steric hindrance approach using a 18 Å long reactive molecule rather than on direct interference of point mutations with modulation by this compound. The modulatory action of CGS 9895 is sensitive to the types of α and β subunit isoforms present in the receptor (Ramerstorfer et al. 2011) . Later, additional CGS 9895 analogues acting either as allosteric modulators or null modulators were described (Varagic et al. 2013a; Varagic et al. 2013b) .
In the present study we were interested to identify point mutations interfering with modulation by CGS 9895. We show that the α1Y209 residue, specifically that located at the α+/β− interface in α1β2γ2 GABAA receptors, is crucial for modulation of the receptor by CGS 9895. We also describe the existence of additional modulatory sites for this compound in the trans membrane domain of the GABAA receptor.
Materials and methods

Construction of mutated receptor subunits
The point mutations α1Y209Q, α1Y209C, α1Y209F, α1S269I, β2N265I and γ2S280I were prepared using the QuikChange TM mutagenesis kit (Stratagene, Agilent Technologies, Basel, Switzerland). The numbering of amino acid residues is based on mature rat sequences.
Expression of GABAA receptors in Xenopus oocytes
Methods used were essentially as described (Middendorp et al. 2015) . Briefly, capped cRNAs were synthesized (Ambion, Austin, TX, USA) from the linearized plasmids with a cytomegalovirus promotor (pCMV vectors) containing the different subunits, respectively. A poly-A tail of about 400 residues was added to each transcript using yeast poly-A polymerase (United States Biologicals, Cleveland, OH, USA). The concentration of the cRNA was quantified on a formaldehyde gel using Radiant Red stain (Bio-Rad) for visualization of the RNA. Known concentrations of RNA ladder (Invitrogen) were loaded as standard on the same gel. cRNAs were precipitated in ethanol/isoamylalcohol 19:1, the dried pellet dissolved in water and stored at −80°C. cRNA mixtures were prepared from these stock solutions and stored at −80°C.
Animal experiments were carried out in strict accordance to the Swiss ethical guidelines, and have been approved by the local committee of the Canton Bern Kantonstierarzt, Kantonaler
Veterinärdienst Bern (BE85/15). Surgery of female adult Xenopus laevis was done under anesthesia (0.2 % tricaine solution). Oocytes were prepared, injected and defolliculated as described previously (Sigel 1987; Sigel and Minier 2005) . Oocytes were injected with 50 nL of the cRNA solution containing wild-type or mutated rat α1, β2 and γ2 subunits of the 6 GABAA receptors at a concentration of 10 nM:10 nM:50 nM (Boileau et al. 2002) . Injected oocytes were incubated in modified Barth's solution at 18°C for at least 24 h before the measurements.
Functional characterization of the GABAA receptors
Currents were measured essentially as described (Middendorp et al. 2015) . Briefly, we used a in agonist concentration around the oocyte. The rate of change was estimated 70% in less than 0.5 s (Sigel et al. 1990 ). The perfusion system was cleaned between drug applications by washing with DMSO to avoid contamination. All media contained a final concentration of 0.5 % DMSO (v/v) to ensure drug solubility.
All data are from as a minimum of three different oocytes from at least two different batches of oocytes. Data represent mean ± SEM. An unpaired t-test was used to compare two means. One-way analysis of variance (ANOVA) was used for multiple comparisons followed by a Tukey post hoc test. * , p < 0.05; * * , p < 0.01; * * * , p < 0.001.
Results
We were interested in determining amino acid residues important for the modulation by CGS 9895 at GABAA receptors. The α1Y209Q mutation has been shown to abolish high affinity binding of Ro 15-1788 and flunitrazepam at the α+/γ− at site 1 . As there are two α1 subunits, there are two α1Y209 residues in a α1β2γ2 receptor. We hypothesized that this mutation would possibly be able to interfere with modulators acting at the α+/β− interface. Here, we report the α1Y209 residue as a major determinant of CGS 9895 action.
Effects of different point mutations of α1Y209 on potentiation by CGS 9895
We examined the consequences of different point mutations of the α1Y209 residue on the potentiation by CGS 9895 of currents elicited by GABA. Wild-type α1β2γ2 receptors and three mutated receptors α1Y209Qβ2γ2, α1Y209Cβ2γ2 and α1Y209Fβ2γ2 were studied. These receptors were expressed in Xenopus oocytes, and investigated using electrophysiological techniques. Fig. 1a indicates the localization of this residue in the receptor, and Fig. 1b shows the structure of CGS 9895. For illustration, the localization of the mutations is shown in the crystalized homomeric β3 receptor (Miller and Aricescu 2014) , where the β3 subunits were renamed α1, β2 and γ2. Fig. 2a shows original current traces obtained for wild-type α1β2γ2
(top) and mutated α1Y209Qβ2γ2 (bottom) receptors. Fig. 2b summarizes the results. For all receptors studied, modulation was measured at a GABA concentration eliciting 0.7-1.2 % of the maximal GABA current amplitude. It should be noted that the mutation α1Y209Q reduces the EC50 for channel opening by GABA in α1β2γ2 GABAA receptors about 2-fold . Potentiation by 10 µM CGS 9895 in α1β2γ2 receptors amounted to 336 ± 6 % (mean ± SEM, n = 11), and was greatly diminished in α1Y209Qβ2γ2 receptors to 38 ± 9 % (mean ± SEM, n = 4, p <0.0001 Tukey posthoc test) and in α1Y209Cβ2γ2 receptors 88 ± 24 % (mean ± SEM, n = 4, p <0.0001 Tukey posthoc test). In α1Y209Fβ2γ2 receptors potentiation was 309 ± 15 % (mean ± SEM, n = 4, p > 0.05 Tukey posthoc test), and did not differ from the potentiation observed in wild-type receptors.
To exclude interaction with the benzodiazepine binding site located at the α+/γ− interface, where CGS 9895 acts as a antagonist (Ramerstorfer et al. 2011) , we studied the effect of potentiation on dual subunit α1β2 receptors. Fig. 3a illustrates original traces for α1β2
(top) and mutant α1Y209Qβ2 (bottom) receptors. Fig. 3b shows the averaged data. In α1β2
receptors, potentiation by 10 µM CGS 9895 amounted to 388 ± 22 % (mean ± SEM, n = 6).
In α1Y209Qβ2 receptors potentiation was reduced to -4 ± 4 % (mean ± SEM, n = 6, p < 0.0001 Tukey posthoc test), and in α1Y209Cβ2 receptors to 43 ± 14 % (mean ± SEM, n = 4, p < 0.0001 Tukey posthoc test). The α1Y209Fβ2 receptor showed a similar potentiation amounting to 465 ± 49 % (mean ± SEM, n = 4, p > 0.05 Tukey posthoc test) as compared to α1β2 receptors.
Therefore replacement of the tyrosine in the α1209 residue by glutamine or cysteine leads to abolishment or a reduction of modulation by CGS 9895. A more conservative mutation to phenylalanine did not affect potentiation. Our results suggest that CGS 9895 acts through the α+/β− interface in the extracellular domain.
Positive allosteric modulation of GABAA receptors by CGS 9895 of α1β2γ2 and α1Y209Qβ2γ2 receptors Fig. 4 shows the concentration-response curves obtained for wild-type α1β2γ2 and α1Y209Qβ2γ2 receptors. The α1β2γ2 receptor was characterized by an EC50 of 7.3 ± 0.8 µM (mean ± SEM, n = 4), and the α1Y209Qβ2γ2 mutant receptor by an EC50 of 26 ± 3 µM (mean ± SEM, n = 4). Thus, this mutation increased the EC50 for CGS 9895 over 3-fold as compared to wild-type receptors. In addition, maximal potentiation was decreased by the mutation. In α1β2γ2 receptor maximal potentiation amounted to 632 ± 148 % (mean ± SEM, n = 4), and in α1Y209Qβ2γ2 mutated receptors 252 ± 59 % (mean ± SEM, n = 4).
Effect of α1Y209Q mutation on potentiation by different structural analogues of CGS 9895
In order to compare the different analogues, we determined the effect of the mutation at a concentration of the respective compound at the concentration effecting half maximal potentiation. We studied the effect of the above point mutation on the potentiation by the structural analogue LAU 177 (Fig. 5) . A former report has indicated that this compound potentiates α1β3 receptors expressed in Xenopus oocytes with an EC50 of 1.0 ± 0.1 µM (Varagic et al. 2013a ). Fig. 1 shows the structure of all analogues studied. LAU 177 differs from CGS 9895 by different substituents in positions 4 and 8. Potentiation by 1 µM LAU 177 in α1β2γ2 receptors amounted to 478 ± 37 % (mean ± SEM, n = 4). In the mutated α1Y209Qβ2γ2 receptor potentiation amounted to 304 ± 30 % (mean ± SEM, n = 4, p = 0.011 t-test). This indicates that LAU 177 is only partially affected by the mutation. 1 µM of the benzodiazepine antagonist Ro 15-1788 did not affect the degree of potentiation in α1β2γ2
receptors. Thus, we excluded that modulation was through the high affinity benzodiazepine binding site (not shown).
We also examined the effect of the α1Y209Q mutation on the potentiation by compounds differing from CGS 9895 only in one position, LAU 176, CGS 8216 and CGS 9896 (Fig. 1b) . As above, the antagonist Ro 15-1788 excluded an action of all these compounds at the benzodiazepine binding site 1 (not shown). 10 µM of the compound CGS 9896 showed a similar potentiation in mutant α1Y209Qβ2γ2 receptors with potentiation amounting to 177 ± 35 % (mean ± SEM, n = 4) as in wild-type α1β2γ2 receptors, with 197 ± 14 % (mean ± SEM, n = 4, p > 0.05 t-test). In contrast, 4 µM LAU 176 showed a markedly decreased potentiation in α1Y209Qβ2γ2 as compared to α1β2γ2 receptors. Potentiation in α1β2γ2 receptors by LAU 176 in was 1607 ± 159 % (mean ± SEM, n = 4) and in the mutated α1Y209Qβ2γ2 receptor 249 ± 21 % (mean ± SEM, n = 4, p = 0.0001 t-test). For 10 µM CGS 8216 potentiation was very small amounting to 56 ± 5 % (mean ± SEM, n = 4) in wild type receptors and to -34 ± 5 % (mean ± SEM, n = 4, p < 0.0001 t-test) in mutated α1Y209Qβ2γ2
receptors.
In wild-type α1β1γ2 receptors, potentiation by compound LAU 176 was dramatically enhanced as compared to LAU 177, whereas it was almost lost for CGS 8216. This observation has been made previously (Varagic et al. 2013a) . Replacement in position R4 of a -CN substituent of -OMe is beneficial for the pair LAU 176/ LAU 177, whereas replacement of -OMe by a -H in this position in CGS 9895 is detrimental for potentiation.
Effect of α1Y209 mutations on potentiation by flurazepam
Since flurazepam has been hypothesized to act with low affinity at the same interface as CGS 9895, namely the α+/β− interface at the extracellular domain (Baur et al. 2008) , we wanted to see if the α1Y209Q mutation affects the response to flurazepam. Thus, we studied the effect of the α1Y209Q mutation in the concentration response curve for flurazepam at α1β2γ2
receptors (Fig. 6) . As shown previously the concentration dependence potentiation is bellshaped in wild-type α1β2γ2 receptors (Baur et al. 2008 ). This bell shape has been interpreted as a positive allosteric modulation through the classical benzodiazepine site (site 1), that is counteracted by occupation of the site at the α+/β− interface (site 2) (Baur et al. 2008) . In the mutated receptor, the concentration dependence of the potentiation by flurazepam was also bell shaped but was greatly shifted to the right. As expected this mutation interferes with the action of flurazepam at the classical benzodiazepine site. At concentrations above 10 µM this compound produced an increase of the current, passing through a maximum at 75-100 µM.
Apparent affinities in wild-type receptors and the mutated receptors through site 1 were 0.4 ± 0.1 µM (mean ± SEM, n = 9) and 37 ± 15 µM (mean ± SEM, n = 4) respectively. Inhibition at high concentration of flurazepam has been interpreted as occupation of site 2 (Baur et al. 2008 ). The point mutation increased the EC50 for site 2 from 64 ± 9 µM (mean ± SEM, n = 9) to 147 ± 18 µM (mean ± SEM, n = 4).
Flurazepam antagonizes potentiation by CGS 9895
Next we studied if flurazepam interferes with CGS 9895 action. For this purpose we used 100
µM and 300 µM of flurazepam to counteract modulation by this compound. At these concentrations flurazepam shows reduced or no potentiation response of α1β2γ2 GABAA receptors ( Fig. 6) (Baur et al. 2008) . 10 µM of CGS 9895 potentiated the response of α1β2γ2 receptors by 347 ± 11 % (mean ± SD, n = 3). Subsequently, the same oocytes were exposed to the combination of 10 µM CGS 9895 and 100 µM of flurazepam, and a residual potentiation amounting to 151 ± 10 % (mean ± SD, n = 3) was observed. In another set of experiments, 10 µM of CGS 9895 potentiated the response of α1β2γ2 receptor by 323 ± 10 % (mean ± SEM, n = 4). When the same oocytes were exposed to the combination of 10 µM CGS 9895 and 300 µM of flurazepam residual potentiation of 18 ± 4 % (mean ± SEM, n = 4) was obtained. An original current trace of the latter experiment is shown in Fig. 7 . As shown in Fig. 6 at a concentration of 300 µM, flurazepam alone nearly fails to affect current elicited by GABA. In α1β2 receptors 10 µM of CGS 9895 potentiated the response by 329 ± 37 % (mean ± SEM, n = 4), subsequently the same oocytes were exposed to the combination of 10 µM CGS 9895 and 300 µM of flurazepam where potentiation amounted to 73 ± 19 % (mean ± SEM, n = 4). The above results indicate that the ability of flurazepam to inhibit modulation by CGS 9895 could be mediated via the same site in the extracellular α+/β− interface.
Alternatively, both modulatory sites must communicate or the effect of their occupation converges at the GABA binding site or on channel gating.
Possible additional sites of action of CGS 9895
Although our observations suggest involvement of the α1Y209 residue situated at the extracellular α+/β− interface in the potentiation by CGS 9895, this compound could still act additionally at other sites in the receptor. Previously, we and others have observed that many hydrophobic substances act at the low affinity site for diazepam on GABAA receptors located at subunit interfaces in the trans membrane region (site 3). We wondered if CGS 9895 would also act at these sites. Triple mutant α1S269Iβ2N265Iγ2S280I receptor has previously been shown to lack low affinity diazepam sites (Walters et al. 2000) . Each mutation is located at different receptor interfaces. Wild-type receptors, α1S269Iβ2γ2, α1β2N265Iγ2, α1β2γ2S280I and α1S269Iβ2N265Iγ2S280I were expressed and investigated. The mutated receptors are abbreviated here as α1M, β2M, γ2M, and α1Mβ2Mγ2M. The potency of GABA for channel gating in all these mutated receptors has previously been described (Maldifassi et al. 2016) . In order to exclude general gating effects caused by these mutations we showed that potentiation by low concentrations of diazepam and by THDOC were not affected (Maldifassi et al. 2016 ).
First we characterized in each receptor the concentration-response relationship for the modulation by diazepam. As shown in Fig. 8a , in wild-type and all mutated receptor forms nM concentrations of diazepam potentiated GABA elicited currents. In α1β2γ2 and α1β2γ2M
receptors the first phase of potentiation reached a plateau at approximately 0.3 µM of
diazepam. An inhibitory phase was observed at wild-type α1β2γ2 receptors at 3-10 µM diazepam and an additional phase of potentiation for both receptors was evident at concentrations above 10-30 µM. Mutated α1Mβ2γ2, α1β2Mγ2, and α1Mβ2Mγ2M receptors lacked this low affinity potentiation by diazepam. The curve was bell-shaped. At high concentrations, approximately 10 µM and above, diazepam produced a significant inhibition of the response to GABA in α1Mβ2γ2, α1β2Mγ2, and α1Mβ2Mγ2M receptors.
Subsequently, we determined the effect of individual site 3 mutations and the triple mutation on potentiation by 10 µM CGS 9895, 10 µM LAU 177 and 200 µM of diazepam. As shown in Fig. 8b , in α1Mβ2γ2 receptors potentiation by 10 µM CGS 9895 was increased to 614 ± 123 % (mean ± SEM, n = 5, p = 0.007 Tukey posthoc test) as compared to wild-type receptors, where potentiation amounted to 337 ± 6 % (mean ± SEM, n = 11) respectively.
Potentiation by CGS 9895 was reduced in the α1β2Mγ2 receptor mutant to 115 ± 15 % (mean ± SEM, n = 4, p = 0.007 Tukey posthoc test). In α1β2γ2M receptors potentiation was increased and amounted to 496 ± 117 % (mean ± SEM, n = 4, p = 0.049 Tukey posthoc test).
Potentiation of the GABA response in α1Mβ2Mγ2M receptors was reduced to 89 ± 9 % (mean ± SEM, n = 7, p = 0.004 Tukey posthoc test).
The single mutations in the α1 and in the β2 subunits altered the degree of potentiation by 10 µM LAU 177. Modulation was also strongly impaired in the triply mutated The above data suggest that additional modulatory sites for CGS 9895 are present at the α+/β−, β+/α−, γ+/β−, and α+/γ− subunit interfaces located in the trans membrane domain of GABAA receptors. On the other hand, the structural analog LAU 177 may harbor modulatory sites at the α+/γ− and β+/α− subunit interfaces. GABAA receptors harbor modulatory sites 3 for diazepam at α+/β−, β+/α−, γ+/β−, and α+/γ− subunit interfaces in the trans membrane domain.
Discussion
The pyrazoloquinoline CGS 9895 at nM concentrations was described as an antagonist at the benzodiazepine high affinity site, but at µM concentrations enhanced GABA induced currents in α1β3 and α1β3γ2 receptors (Ramerstorfer et al. 2011) . Using a steric hindrance approach together with a homology model of GABAA receptors , several possible pocket-forming amino acids at the α+/β− subunit interface were mutated to cysteine.
Modification with MTSEA-biotin of the mutated residues α1S204C, α1V211C and β364C
considerably reduced modulation by CGS 9895, indicating that this compound acts within 18 Å of the mutated residues (Ramerstorfer et al. 2011) . Because of the length and flexibility of MTSEA-biotin, specific amino acids in contact with CGS 9895 were not identified (Ramerstorfer et al. 2011) . Our results indicate that the α1Y209 residue located at the α+/β− interface is important for CGS 9895 action and additionally suggest binding sites at all five subunit interfaces in the trans membrane region.
As the α1β2γ2 receptor contains two α1 subunits, there are two α1Y209 residues in the receptor. One residue is located at the α+/γ− interface in the extracellular domain of the receptor (site 1), and is part of the diazepam-binding pocket (Amin et al. 1997; Buhr et al. 1997) . The other residue is located at the extracellular part of the α+/β− interface homologous to the residue located at site 1. Mutation to Q of the α1Y209 residue leads to loss of Ro15-1788 and flunitrazepam binding at the high affinity diazepam site and reduces the EC50 for channel opening by GABA about 2-fold . We studied if the mutation of this residue might also interfere with the action of modulators supposedly acting at the extracellular α+/β− interface.
We found that mutations in the α1Y209 residue affected the ability of CGS 9895 to potentiate GABA elicited currents at GABAA receptors. Replacement of tyrosine in the α1209 residue for the non-aromatic amino acids glutamine or cysteine, led to a dramatic reduction on the action of CGS 9895. When the same tyrosine residue was replaced with phenylalanine, leading to the removal of the hydroxyl group in the benzene ring, potentiation remained almost unaffected. Thus, the aromatic ring in the α1Y209 residue is essential for the interaction of the receptor with CGS 9895. The α1Y209Q mutation led to an increase of the EC50 for CGS 9895, and a decrease in the maximal potentiation obtained. Similar observations were made in α1β2 and α1β2γ2 receptors, indicating that indeed the residue at the α+/β− subunit interface is important. It should be noted that in case a point mutation affects modulation by a compound, the corresponding residue can be involved in the formation of the binding pocket, or alternatively it may affect the allosteric transduction required for modulation. At least the ability of GABA to gate the channel is nearly unaffected by the α1Y209Q mutation .
Structural analogs of CGS 9895 were investigated for their sensitivity to mutations in the α1Y209 residue. All compounds investigated contained a common pyrazoloquinolinone nucleus, with different substituents in R4 and R8 (Fig. 1b) . EC50 and efficacy (10 µM) of the compounds in α1β3 receptors have been described elsewhere (Varagic et al. 2013a) . CGS 9895 and LAU 176, are both sensitive to the studied mutation, and have both a -OMe group at position R4, but they differ in the R8 position, where the first has a -H and the latter a -OMe group. Potentiation by CGS 9896 is not significantly affected and that by LAU 177 partially by the α1Y209Q mutation. CGS 9896 has a -Cl at position R4, and at R8 a hydrogen atom.
LAU 177 has a -CN group at the position R4, and a -OMe group at R8. CGS 8216, which contains -H in both positions was the weakest modulator of GABA currents in α1β2γ2 receptors. A similar result was obtained previously using α1β3 receptors (Varagic et al. 2013a ). From our observations we conclude that the methoxy group at the R4 may be responsible for the sensitivity of these compounds to the α1Y209Q mutation and might be apposed to this residue.
Previously, a low affinity site for flurazepam has been postulated at the α+/β− subunit interface. We were interested if flurazepam and CGS 9895 interacted at the same site. We found a) that the mutation α1Y209Q not only affects modulation by CGS 9895 but also (Ramerstorfer et al. 2011) . Since this negative modulatory effect could not be abolished by modification with MTSEA-biotin of α1S204C, α1V211C and β364C, the authors concluded that flurazepam effects must be mediated through a different site (Ramerstorfer et al. 2011 ).
The five-subunit interfaces of GABAA receptors harbor modulatory sites for high concentrations of diazepam (sites 3). We also investigated if CGS 9895 is affected by mutations in these sites. Potentiation by CGS 9895 was reduced in the triple mutant receptor and by the β2N265I mutation, and increased by the mutations α1S269I and γ2S280I. We concluded that the five-subunit interfaces of GABAA receptors bear modulatory sites for CGS 9895. The fact the β1S290N mutation leads to loss of stimulation by CGS 9895 in α1β1 receptors (Ramerstorfer et al. 2011) were previously interpreted as allosteric effect. The structural analog LAU 177 was also sensitive to some of the site 3 mutations. Potentiation was reduced in the triple mutant receptor, as by the α1S269I and β2N265I mutations, however it was not affected by the γ2S280I mutation. Therefore only the β+/α−, α+/β−, and α+/γ− GABAA receptor subunit interfaces have modulatory sites for this compound.
In summary, we show that α1Y209 at the α+/β− interface in the extracellular domain is a key residue for CGS 9895 action in GABAA receptors and that it may be in contact with the -OMe substituent of this compound. Additionally, the GABAA receptor harbors modulatory sites for this compound at subunit interfaces in the membrane. Fig. 1 (a) Model structure of the GABAA receptor transmembrane domain. The receptor is composed of two α (yellow), two β (blue), and one γ (red) subunits; structures are shown in ribbon representation.
Legends to figures
Shown in orange are the αY209 residues located at the extracellular α+/β-and α+/γ-interfaces. The model structure depicts the crystalized homomeric β3 GABAA receptor (PDB structure 4COF) (Miller and Aricescu 2014) . Some of the β3 subunits were renamed α1, β2 and γ2. Experiments were performed four to eleven times with different oocytes from at least three different batches; data are expressed as mean ± SEM. and 10 µM CGS 9896 in wild-type and mutant α1Y209Qβ2γ2 receptors. Experiments were performed four to six times using different oocytes; data are expressed as mean ± SEM. 
